Navigation Links
Beckman Coulter Announces Fourth Quarter and Full Year 2008 Results; Earnings Outlook Achieved on Strong Fundamentals
Date:2/9/2009

rted total revenue to be flat. We anticipate that cash instrument sales in the current economic climate will slow, compared with the robust growth of cash instrument sales in the first half of 2008. However, solid recurring revenue growth is expected to continue," Garrett said.

"Operating margin is anticipated to be between 11.7% and 12%, after absorbing a significant currency head wind and a $25 million increase in pension expense. We are committed to zero overhead growth resulting in flat operating expense. At current exchange rates, non-operating expense should be around $22 million, due to expected gains on hedging contracts. Based on an estimated tax rate of 26% to 27% and a flat share count, earnings per fully diluted share should be between $3.85 and $4.05. The planned pacing of earnings growth is uneven, with as much as 65% of net earnings expected to come in the second half of the year, due to slowed growth of cash instrument sales and currency shifts in the first half. Capital expenditures are expected to be $350 to $375 million, and depreciation and amortization should be between $270 and $290 million.

"2009 will, no doubt, be a challenging year. However, we began to adjust our spend rate last summer when the U.S. Dollar strengthened dramatically. We believe we have identified and begun to implement changes necessary to deliver on our commitments. Solid trending of recurring revenue and positive cost management initiatives implemented in 2008 give us confidence that our 2009 goals are achievable," Garrett concluded.

Investor Conference Call

As previously announced, there will be a conference call today, Monday, February 9, 2009 at 5:00 pm ET to discuss the fourth quarter and full year ended December 31, 2008 results. The call will also be webcast live. The call is accessible to all investors through Beckman Coulter's website at

SOURCE Beckman Coulter - IR
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33

Related biology technology :

1. Beckman Coulter to Present at the Bear Stearns Healthcare Conference
2. Beckman Coulter to Present at the UBS Global Life Sciences Conference
3. Beckman Coulter Announces Third Quarter 2007 Earnings to Be Released on Tuesday, October 30, 2007 Before Market Opens
4. Beckman Coulter Declares Quarterly Dividend
5. Beckman Coulter Announces Third Quarter 2007 Results
6. Beckman Coulter to Present at the 19th Annual Piper Jaffray Healthcare Conference
7. Beckman Coulter to Present at the Lazard Capital Markets Fourth Annual Healthcare Conference
8. Beckman Coulter to Acquire Exclusive Rights to Break-Through Technologies
9. Beckman Coulter Elects AMN Healthcare Executive to Board of Directors
10. Beckman Coulter to Present at the JPMorgan Healthcare Conference
11. AcroMetrix Signs Development and Supply Agreement With Beckman Coulter Inc. for Molecular Quality Control Standards
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/3/2015)... Medical, Inc. (Nasdaq: AEMD ), the pioneer in ... announced that it will host its First Quarter Fiscal ... 13, 2015 at 4:30 p.m. Eastern Time. ... fiscal 2016 first quarter results.  A recorded version of ... the call at the Investor Relations portion of the ...
(Date:8/3/2015)... 3, 2015 According to a ... Cell Culture: Asia to Witness ... the global 3D cell culture market was valued at US$ 586.1 ... a CAGR of 29.1% to account for US$ 2,717.6 ... TOC:  http://www.persistencemarketresearch.com/market-research/3d-cell-cultures-market.asp 3D cell culture refers ...
(Date:7/31/2015)... 2015 In today,s fast changing healthcare ... drive positive health outcomes, improve profitability and enhance ... care in their communities. At ThoughtSpot 2015, ... AmerisourceBergen announced a new set of innovative capabilities ... and help independent pharmacies endure the industry,s most ...
(Date:7/31/2015)... ... 2015 , ... R-Biopharm is proud to announce the RIDASCREEN® ... foods, has been accepted by AOAC International as Official First Action method. The ... Products by R5 Competitive ELISA,” based on a specific monoclonal antibody to potentially ...
Breaking Biology Technology:Aethlon Medical To Host First Quarter Fiscal 2016 Investor Call on August 13, 2015 2Global 3D Cell Culture Market Will Reach US$ 2,717.6 Million by 2020: Persistence Market Research 2Global 3D Cell Culture Market Will Reach US$ 2,717.6 Million by 2020: Persistence Market Research 3Global 3D Cell Culture Market Will Reach US$ 2,717.6 Million by 2020: Persistence Market Research 4AmerisourceBergen Unveils Suite of Enhanced Capabilities for Independent Pharmacies at ThoughtSpot 2015 2AmerisourceBergen Unveils Suite of Enhanced Capabilities for Independent Pharmacies at ThoughtSpot 2015 3RIDASCREEN® Competitve Gliadin Receives AOAC Official First Action Status 2
... EMERYVILLE, Calif., Aug. 3 Bionovo, Inc. (Nasdaq: ... second quarter of fiscal year 2009 ended June 30, 2009 on Monday, ... cast to review the financial results on Monday, August 10, 2009 at ... the call by dialing (800) 860-2442 or (412) 858-4600, or can listen ...
... , , , ... Inc. (Nasdaq: SNMX ), a leading company focused on ... the food, beverage, and ingredient supply industries, and Firmenich SA, the ... have entered into a collaborative research, development, commercialization and license agreement ...
... , , EMERYVILLE, ... NBY ) today announced that Roy J. Wu ... business development. Wu brings to NovaBay more than 30 ... with increasingly responsible management positions in global business development, ...
Cached Biology Technology:Bionovo, Inc. to Announce Second Quarter Fiscal Year 2009 Financial Results on Monday, August 10, 2009 2SENOMYX AND FIRMENICH TO COLLABORATE ON DISCOVERY, DEVELOPMENT AND WORLDWIDE COMMERCIALIZATION OF NOVEL SWEET ENHANCERS 2SENOMYX AND FIRMENICH TO COLLABORATE ON DISCOVERY, DEVELOPMENT AND WORLDWIDE COMMERCIALIZATION OF NOVEL SWEET ENHANCERS 3SENOMYX AND FIRMENICH TO COLLABORATE ON DISCOVERY, DEVELOPMENT AND WORLDWIDE COMMERCIALIZATION OF NOVEL SWEET ENHANCERS 4SENOMYX AND FIRMENICH TO COLLABORATE ON DISCOVERY, DEVELOPMENT AND WORLDWIDE COMMERCIALIZATION OF NOVEL SWEET ENHANCERS 5NovaBay(R) Pharmaceuticals Names Roy J. Wu as Senior Vice President for Business Development 2NovaBay(R) Pharmaceuticals Names Roy J. Wu as Senior Vice President for Business Development 3
(Date:7/21/2015)... , July 21, 2015  NXT-ID, Inc. ... a biometric authentication company focused on the growing ... smart wallet, announces that it has filed provisional ... and Method. This invention highlights ... only authorizes an account, but also the user ...
(Date:7/13/2015)... , Jul. 13, 2015 NXT-ID, Inc. (NASDAQ: ... biometric authentication company focused on the growing mobile ... provisional patent 62/188684 for BEHAVIORAL-DIRECTED AUTHENTIATION ... new convenient and secure method to make payments.  ... payment methods, introduced with its groundbreaking voice-direct payment ...
(Date:7/9/2015)... SAN JOSE, Calif. , July 9, ... ), the leading developer of human interface ... authentication technology, the industry,s first fully hardware ... innovative Match-in-Sensor secure authentication technology is literally ... pattern storage and biometric matching within the ...
Breaking Biology News(10 mins):NXT-ID Patents Personalized Tokenized Payments for Next Generation Secure Payment Technology 2NXT-ID Patents Personalized Tokenized Payments for Next Generation Secure Payment Technology 3NXT-ID Patents Personalized Tokenized Payments for Next Generation Secure Payment Technology 4NXT-ID Patents Behavior-Directed Payments 2NXT-ID Patents Behavior-Directed Payments 3NXT-ID Patents Behavior-Directed Payments 4Synaptics Announces World's First Match-in-Sensor Fingerprint Authentication Technology 2Synaptics Announces World's First Match-in-Sensor Fingerprint Authentication Technology 3
... a common feature of prion disease-affected human, mouse, and ... Neena Singh and colleagues at Case Western Reserve University ... findings, published March 13 in the open-access journal ... of neurotoxicity in prion disorders, and novel avenues for ...
... Kansas State,University, with collaboration from Epitopix LLC, have ... E. coli O157 in beef cattle. ... the post-harvest food safety,aspect, whether it,s E. ... College of Veterinary Medicine. Thomson is the Jones,Professor ...
... German . The Aarhus University ... between the many conference participants and according to ... Kyoto was very successful in doing so: "I am ... will undoubtedly contribute significantly to the future climate debate ...
Cached Biology News:Iron is involved in prion disease-associated neuronal demise 2K-State researchers help Epitopix license the United States' first E. coli O157 vaccine for cattle 2Seven recommendations from Aarhus to COP15 2Seven recommendations from Aarhus to COP15 3
... Pulser Xcell microbial system, 100 to ... for electroporation of bacterial and fungal ... unit, PC module for exponential decay ... cuvettes (5 each of 0.1 and ...
... yellow solution. In PBS ... and other proprietary stabilizers; ... formulated to stabilize activity ... conjugates at high conjugate ...
... Xcell eukaryotic system, 100 to ... used for electroporation of mammalian ... main unit, CE module for ... square-wave pulses, ShockPod shocking chamber, ...
... on Macintosh operating systems to predict ... sequence up to 3,200 bases, which ... and GC clamps for mutation detection ... constant denaturing gel electrophoresis (CDGE), and ...
Biology Products: